We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

HomeHormone TherapyNon-Hormonal Menopause TreatmentNew York
Mid-Atlantic · Telehealth Available

Non-Hormonal Menopause Care for Women in New York

Written by the Kindr Health Editorial & Clinical TeamMedically reviewed by Kindr Health Clinical Team NPI 1609792902Published Last reviewed

For women who cannot or prefer not to use hormone therapy, evidence-based non-hormonal treatments including paroxetine and desvenlafaxine are available — targeting vasomotor symptoms and mood disruption without estrogen. Available to women across New York's humid continental climate — entirely online.

Start Your Free Intake →

Licensed in New York · FDA-registered pharmacy · Reviewed within 24 hours · Ships free

Is Non-Hormonal Menopause Treatment right for women in New York?

Connect with a kindr-licensed provider who can evaluate whether Non-Hormonal Menopause Treatment is appropriate for your health history and symptoms — from anywhere in New York.

  • Hot flashes and night sweats
  • Mood changes and anxiety
  • Sleep disruption
  • Cannot or prefer not to use estrogen
  • History of hormone-sensitive conditions

Non-Hormonal Menopause Treatment in New York: what is specific to your state

About ~2.6M of women in New York are in the midlife hormonal band right now, spread from Albany out to New York City, Buffalo, Rochester, Yonkers. New York City and Westchester carry extraordinary specialist density, while the North Country, Southern Tier and western rural counties look like shortage areas by comparison.

Every clinician who treats you holds a full, active New York license in good standing with the New York State Board for Professional Medical Conduct, and prescribes only within the standards that board sets — a documented history, a real evaluation, and a written record for each prescription. Any pharmacy dispensing to a New York address is licensed with the New York State Board of Pharmacy. We do not bill New York Medicaid or commercial New York plans; care is a flat monthly subscription, and we will provide an itemised receipt if you want to submit it yourself.

New York sits in Mid-Atlantic with a humid continental climate, and that shows up in how symptoms present here. High specialist density in NYC but long waits; outside NYC the gap is dramatic. Kindr serves every county.

Licensing board
New York State Board for Professional Medical Conduct
Pharmacy regulator
New York State Board of Pharmacy
State Medicaid program
New York Medicaid
Region
Mid-Atlantic
Capital
Albany
Largest metros served
New York City, Buffalo, Rochester

Moved recently, or split your year across state lines? Care continues wherever our clinicians are licensed. Nearby coverage: New Jersey · Pennsylvania · Connecticut · Massachusetts · Vermont

What is non-hormonal menopause treatment?

Non-hormonal menopause treatments are prescription medications that reduce vasomotor symptoms (hot flashes, night sweats) and, in many cases, associated mood and sleep disruption — without altering estrogen or progesterone levels. The category includes select SSRIs and SNRIs (paroxetine, desvenlafaxine, escitalopram, venlafaxine), gabapentin, and the newer neurokinin-3 receptor antagonist fezolinetant.

These medications are the standard of care for women with a history of hormone-sensitive cancer, personal or strong family history of venous thromboembolism, or other conditions where estrogen is contraindicated — and for women who simply prefer a non-hormonal approach.

How non-hormonal menopause treatment works

SSRIs and SNRIs modulate serotonin and norepinephrine signaling in the hypothalamic thermoregulatory center, reducing the exaggerated heat-loss response that produces hot flashes. Gabapentin acts through calcium channel modulation and is especially useful for nighttime symptoms. Fezolinetant blocks neurokinin-3 receptors on hypothalamic KNDy neurons, directly reducing the neurologic driver of vasomotor symptoms discovered in recent decade of menopause research.

The clinical evidence

Paroxetine (7.5 mg) is the only FDA-approved non-hormonal medication specifically labeled for vasomotor symptoms of menopause, based on two randomized controlled trials showing significant reduction in hot flash frequency and severity. Fezolinetant (Veozah), FDA-approved in 2023, showed 55-65% reduction in moderate-to-severe hot flashes at 12 weeks in the SKYLIGHT trials — comparable to hormone therapy.

NAMS 2023 non-hormonal position statement identifies fezolinetant, paroxetine, desvenlafaxine, escitalopram, gabapentin, and oxybutynin as evidence-based options for vasomotor symptoms in women who cannot or choose not to use hormone therapy.

Who is a good candidate?

  • Women with a personal history of hormone-sensitive breast or endometrial cancer
  • Women with history of venous thromboembolism or elevated thrombotic risk
  • Women with hormone-related contraindications to estrogen
  • Women whose primary symptoms are mood-driven alongside vasomotor
  • Women who prefer a non-hormonal option regardless of eligibility for HRT

Contraindications

  • Concurrent tamoxifen use with paroxetine (paroxetine inhibits its activation)
  • Known hypersensitivity to the specific medication
  • Active bipolar disorder (SSRI/SNRI cautions)
  • Severe hepatic impairment (fezolinetant)
  • Combination with monoamine oxidase inhibitors

Common side effects

Most side effects are mild and settle within the first 4-8 weeks. Report anything severe or persistent to your prescriber.

  • Nausea in the first 1-2 weeks of SSRIs/SNRIs
  • Dizziness or fatigue with gabapentin
  • Sexual side effects with some SSRIs
  • Elevated liver enzymes (fezolinetant — monitored with routine labs)
  • Discontinuation symptoms if stopped abruptly

Alternatives to consider

Fezolinetant (Veozah)
Newest, non-hormonal, hormone-therapy-comparable efficacy
Cognitive behavioral therapy
Evidence-based for hot flashes and sleep
Weight loss and lifestyle
Meaningful reductions in vasomotor symptom burden
Vaginal estrogen (local only)
Compatible with most non-hormonal protocols for GSM

Sources

  1. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
  2. Depypere H et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms: the SKYLIGHT 1 and 2 trials. Menopause. 2023.
  3. Simon JA et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms. Menopause. 2013;20(10):1027-1035.
  4. Stuenkel CA et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.

Medically reviewed by the kindr Clinical Team. Content reflects the 2022 NAMS Position Statement and current Endocrine Society guidelines. Last reviewed 2026.

How kindr delivers care in New York

Step 1

Complete your intake online from anywhere in New York

Step 2

A licensed New York provider reviews within 24 hours

Step 3

If prescribed, ships free to your door

A kindr physician reviews your health history and reasons for avoiding HRT. Non-hormonal prescription alternatives are evaluated and prescribed where clinically appropriate — shipped monthly.

What to expect

  • Weeks 1-2
    Early tolerance established; initial mild symptom reduction
  • Weeks 4-6
    Meaningful hot flash reduction (fezolinetant faster)
  • Weeks 8-12
    Full effect established; dose refinement complete
  • Months 6+
    Long-term maintenance and reassessment

In 2025, the FDA updated its guidance on hormone therapy for menopause, removing longstanding warnings that had deterred many women from effective treatment. Speak with a kindr provider about what this means for you.

Clinical standards in New York

Board-certified MDs and DOs licensed in New York
FDA-registered 503A pharmacy fulfillment
HIPAA compliant and SOC 2 certified
Telehealth permitted under state law

New York frequently asked questions

Non-Hormonal Menopause Treatment in nearby states

New JerseyMassachusettsPennsylvania

Ready to speak with a New York-licensed provider?

Connect with a board-certified kindr physician licensed to practice in New York. No waiting rooms. No referrals. Reviewed within 24 hours.

Start Your Free Intake →

Non-Hormonal Menopause Treatment is a prescription medication. A licensed provider must evaluate whether this treatment is right for you. kindr is not a pharmacy. Medications are prescribed by licensed independent physicians and fulfilled by FDA-registered 503A compounding pharmacies. kindr does not guarantee any specific treatment will be prescribed.